Trial Profile
Sitagliptin (MK0431) Late Phase II Double-Blind Dose-Response Study - Type 2 Diabetes Mellitus.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Sitagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Merck & Co; Merck Sharp & Dohme
- 17 Sep 2008 Actual patient number (363) added as reported by ClinicalTrials.gov.
- 17 Sep 2008 Actual end date (Mar 2006) added as reported by ClinicalTrials.gov.
- 17 Sep 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.